EW
NYSE · Health Care
Edwards Lifesciences Corp
$81.69
-0.33 (-0.40%)
Performance
1D
—
1W
—
1M
—
3M
-5.94%
6M
+7.13%
1Y
+14.67%
YTD
-4.27%
Open$81.65
Previous Close$82.02
Day High$82.33
Day Low$80.60
52W High$87.89
52W Low$65.94
Volume—
Avg Volume6.10M
Market Cap45.80B
P/E Ratio42.66
EPS$1.83
SectorHealth Care
Technical Indicators
Full analysis →
SMA 50
$82.97
Below
SMA 200
$79.63
Above
RSI (14)
42.7
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
43 analysts
Price Target
+28.2% upside
Current
$81.69
$81.69
Target
$104.74
$104.74
$71.58
$104.74 avg
$133.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.05B | 5.81B | 13.78B |
| Net Income | 1.07B | 924.82M | 1.76B |
| Profit Margin | 17.7% | 16.8% | 12.8% |
| EBITDA | 1.12B | 1.02B | 3.56B |
| Free Cash Flow | — | — | 1.63B |
| Rev Growth | +4.1% | +4.1% | +2.8% |
| Debt/Equity | 0.06 | 0.06 | 0.15 |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is a global leader in patient-focused innovations for structural heart disease and critical care monitoring, headquartered in Irvine, California. The company's primary products include transcatheter aortic valve replacement systems, surgical heart valves, and hemodynamic monitoring technologies used in cardiac and intensive care settings. Edwards is the world's leading manufacturer of heart valve therapies and pioneered the transcatheter aortic valve implantation procedure, which has become a standard of care for patients with severe aortic stenosis. Its products are sold in more than 100 countries through a combination of direct sales and distributor channels.
Health Care Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc | $272.28 | +1.02% | 21.7 | 261.12B |
| ABT | Abbott Laboratories | $104.06 | -0.75% | 28.3 | 184.68B |
| ISRG | Intuitive Surgical Inc | $471.91 | -1.28% | 59.8 | 170.78B |
| SYK | Stryker Corp | $328.51 | -1.23% | 39.5 | 128.28B |
| MDT | Medtronic Plc | $86.58 | -0.68% | 24.1 | 111.30B |
| MCK | Mckesson Corp | $881.94 | +0.56% | 25.1 | 109.03B |
EW Frequently Asked Questions
What does Edwards Lifesciences do?
Edwards Lifesciences generates the vast majority of its revenue from TAVR—transcatheter aortic valve replacement—a minimally invasive procedure that replaces a diseased aortic valve without open-heart surgery. The company pioneered and commercialized TAVR, which has become the standard of care for severe aortic stenosis patients. It also sells surgical heart valves for patients who do require open-chest procedures, and recently divested its critical care hemodynamic monitoring business to Becton Dickinson to sharpen its structural heart focus.
Is EW stock a good investment?
Edwards benefits from an aging global population driving durable growth in structural heart disease procedures, particularly TAVR. The company's clinical data and physician relationships built over decades create meaningful switching costs. However, Medtronic and Boston Scientific have introduced competing TAVR systems that are gradually narrowing Edwards' market share in certain patient populations. The stock typically trades at a premium valuation reflecting its category leadership and durable demand backdrop.
Who are Edwards Lifesciences' main competitors?
Medtronic's Evolut platform is the primary TAVR competitor, with substantial procedure volume and an expanding low-risk patient indication. Boston Scientific has entered TAVR with its Acurate and Myval systems, particularly strong in Europe. Abbott Laboratories competes in certain structural heart segments. LivaNova is a smaller competitor in heart surgery products. All major cardiac device companies are investing heavily in structural heart, intensifying the competitive landscape.
What makes EW stock unique?
Edwards built and largely defined the TAVR market through decades of clinical investment, giving it the deepest body of long-term outcomes data of any competitor. Its singular focus on structural heart disease—sharpened further by the critical care divestiture—means R&D, commercial, and manufacturing resources are concentrated rather than spread across dozens of device categories. That focus has produced consistently strong TAVR procedure volume growth and premium margins.
What is EW's stock price today?
EW last closed at $81.69, down 0.40% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $65.94 and a high of $87.89. The current price represents 72% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What do Wall Street analysts say about EW?
Among 43 analysts covering EW, the consensus rating is Buy — 31 rate it a buy, 12 hold, and 0 sell. The average price target sits at $104.74, implying 28% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Is Edwards Lifesciences Corp profitable?
Edwards Lifesciences Corp generated $6.05B in revenue during fiscal year 2026, with $1.07B reaching the bottom line as net income. The net profit margin of 17.7% is solid for its sector.
What is EW's P/E ratio?
EW trades at a P/E ratio of 42.66 on trailing earnings of $1.83 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
How has EW stock performed recently?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -5.94% (3M), +7.13% (6M), +14.67% (1Y), -4.27% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether EW is outperforming or lagging the broader market.